Electrolyte disorders associated with the use of anticancer drugs

详细信息    查看全文

• 作者：George Liamis ; Theodosios D. Filippatos ; Moses S. Elisaf ; ^{egepi@cc.uoi.gr" class="auth_mail" title="E-mail the corresponding author}
• 关键词：ADH ; antidiuretic hormone ; AQP-2 ; aquaporin-2 ; EGF ; epidermal growth factor ; EGFR ; epidermal growth factor receptor ; NDI ; nephrogenic diabetes insipidus ; PTH ; parathormone ; ROMK channels ; renal outer medulla K+ channels ; SIADH ; syndrome of inappropriate antidiuretic hormone secretion ; TRPM6 ; Mg++ transient receptor potential ion channel 6
• 刊名：European Journal of Pharmacology
• 出版年：2016
• 出版时间：15 April 2016
• 年：2016
• 卷：777
• 期：Complete
• 页码：78-87
• 全文大小：599 K

文摘

The use of anticancer drugs is beneficial for patients with malignancies but is frequently associated with the occurrence of electrolyte disorders, which can be hazardous and in many cases fatal. The review presents the electrolyte abnormalities that can occur with the use of anticancer drugs and provides the related mechanisms. Platinum-containing anticancer drugs induce hypomagnesemia, hypokalemia and hypocalcemia. Moreover, platinum-containing drugs are associated with hyponatremia, especially when combined with large volumes of hypotonic fluids aiming to prevent nephrotoxicity. Alkylating agents have been linked with the occurrence of hyponatremia [due to syndrome of inappropriate antidiuretic hormone secretion (SIADH)] and Fanconi’s syndrome (hypophosphatemia, aminoaciduria, hypouricemia and/or glucosuria). Vinca alkaloids are associated with hyponatremia due to SIADH. Epidermal growth factor receptor monoclonal antibody inhibitors induce hypomagnesemia, hypokalemia and hypocalcemia. Other, monoclonal antibodies, such as cixutumumab, cause hyponatremia due to SIADH. Tyrosine kinase inhibitors are linked to hyponatremia and hypophosphatemia. Mammalian target of rapamycin inhibitors induce hyponatremia (due to aldosterone resistance), hypokalemia and hypophosphatemia. Other drugs such as immunomodulators or methotrexate have been also associated with hyponatremia. The administration of estrogens at high doses, streptozocin, azacitidine and suramin may induce hypophosphatemia. Finally, the drug-related tumor lysis syndrome is associated with hyperphosphatemia, hyperkalemia and hypocalcemia. The prevention of electrolyte derangements may lead to reduction of adverse events during the administration of anticancer drugs.